

Convenient Synthesis of a Central 2,3,6-Trisubstituted Pyridine Skeleton of a Macrobicyclic Antibiotic, Cyclothiazomycin

Akihiro Okabe, Akinori Ito, Kazuo Okumura, and Chung-gi Shin*

Laboratory of Organic Chemistry, Faculty of Technology, Kanagawa University, Kanagawa-ku, Yokohama 221-8686

(Received January 31, 2001; CL-010091)

The first convenient synthesis of the main central 2,3,6-trisubstituted pyridine skeleton [protected Fragment A-B] of a macrobicyclic antibiotic, cyclothiazomycin, was achieved.

Cyclothiazomycin (**1**),¹ isolated from the culture of *Streptomyces NR0516*, is a macrobicyclic antibiotic and features a unique structure. The main pyridine skeleton [Fragment A-B: **2**] is composed of a central 2,3,6-trisubstituted pyridine skeleton [Fragment B: **4**] and a bithiazolylthiazoline segment [Fragment A: **3**], as shown in Figure 1. Recently, we have reported a novel synthesis of an *N*-protected 2-[2-(1-aminoethenyl)bithiazolyl]thiazoline-4-carboxylate derivative [protected Fragment A: (P)-**3**].^{2,3}

In connection with the total synthesis of **1**, herein we wish to report a convenient synthesis of the main central pyridine skeleton [protected Fragment A-B: (P)-**2**].





Figure 1. Retrosynthesis of **1**.

First of all, to synthesize the Fragment B derivative, 3-cyano-6-(dimethoxymethyl)-2-pyridone (**5**)⁴ was converted to the corresponding 3-methyl ester **7** via the 3-carboxylic acid **6**. Triflation of **7** with triflic anhydride (Tf₂O) gave the 2-trifloxy pyridine derivative **8**, the TfO group of which was then treated with ethyl vinyl ether in the presence of Pd(OAc)₂ and dppp⁵ to give the 2-(ethoxyvinyl)pyridine derivative **9**. Conversion of the ethoxyvinyl group to an acetyl group by using 70% AcOH, followed by simultaneous reduction of both the acetyl and methoxycarbonyl groups with NaBH₄ in the presence of CaCl₂ gave the 2-(1-hydroxyethyl)-3-(hydroxymethyl)pyridine derivative **11** as a racemate. Subsequent protection of the primary alcohol with *t*-butyldiphenylsilyl chloride (TPSCI) gave

the 3-(TPSO-methyl)pyridine derivative **12**, and then the secondary alcohol was azided with mesyl chloride (MsCl) and NaN₃ to give the 2-(1-azidoethyl)pyridine derivative **13**. Hydrogenolysis of the azido group with 10% Pd-C/H₂ gave the 2-(1-aminoethyl)pyridine derivative **14**, the amino group of which was protected with Boc₂O to give the expected 2-[1-(*N*-Boc)aminoethyl]pyridine derivative **15**, as shown in Scheme 1.




Scheme 1. Reagents: i) 6 M KOH, EtOH, ii) H⁺, MeOH, iii) Tf₂O, DMAP, pyridine, iv) Pd(OAc)₂, dppp, Ethyl vinyl ether, Et₃N, toluene, v) 70% AcOH, THF, vi) NaBH₄, CaCl₂, EtOH, vii) TPSCI, Et₃N, DMAP, CHCl₃, viii) a) MsCl, Et₃N, CH₂Cl₂, b) NaN₃, DMF, ix) H₂, 10% Pd-C, EtOH, x) Boc₂O, Et₃N, CHCl₃.

Furthermore, hydrolysis of the 6-acetal group of **15** with 2 M HCl, followed by thiazolation of the formed 6-formylpyridine derivative **16** with H-L-Cys-OMe and then oxidation with MnO₂ by the Shioiri method⁶ gave the (pyridin-6-yl)thiazole-4-carboxylate **17**. After hydrolysis of the methyl ester with 1 M LiOH, the obtained free acid **18** was esterified again with phenacyl bromide (PacBr) to give the Pac ester **19**. Deprotection of the TPS group by using tetrabutylammonium fluoride (TBAF), followed by oxidation with the Jones reagent gave the corresponding lactam derivative **21**. After hydrolysis of the Pac ester with K₂CO₃ aq solution, coupling with H-L-Ser(TBS)-OBu^t (TBS=*t*-butyldimethylsilyl) by the diphenylphosphinic azide (DPPA) method gave the dipeptide derivative **23** as a diastereomeric mixture. Then, ring cleavage of the lactam with 1 M LiOH gave the 3-carboxylic acid **24**, which was esterified with BnBr and then thioamidated with Lawesson's reagent to give the expected thiocarbonyl derivative **26**. Subsequently, after deprotection of the TBS group of **26** with 2 M HCl, separation of the obtained mixture on a silica-gel column using a mixture of CHCl₃ and acetone (50 : 1 v/v) gave each diastereomer **27** and **28**. Thiazolation of the two isomers with the Mitsunobu reagent gave the corresponding (pyridin-6-yl)thiazolylthiazoline derivatives **29**⁷ and **30** respectively. In order to examine whether **29** and **30** are diastereomers or not, further oxidation of the thiazoline ring with TBAF gave the corresponding bithiazole derivatives **31** and **32** respectively, as

shown in Scheme 2. As a result, it was found that the physical (IR and ^1H NMR) and chemical constants (mp and elemental analysis) were completely identical, but the signs of the specific rotation were reversed. These facts clearly indicate that the compounds **29** and **30** as well as **27** and **28** are diastereomeric isomers; further, **31** and **32** are enantiomer to each other.

Furthermore, in order to determine the configuration of the 2-(1-aminoethyl) group of the synthetic **29** and **30**, (*R*)- and (*S*)-configurational 2-(1-aminoethyl)pyridines **36** were synthesized, and the CD spectra of **36** were compared with those of **29** and **30**.




Scheme 2. Reagents: i) 2 M HCl, THF, ii) a) HCl·H-Cys-OMe, Et₃N, toluene, b) MnO₂, toluene, iii) 1 M LiOH, H₂O-dioxane (1:1 v/v), iv) PacBr, Et₃N, DMF, v) TBAF, THF, vi) Jones reagent, acetone, vii) K₂CO₃, THF, H₂O, viii) H-Ser(TBS)-OBu^t, DPPA, Et₃N, DMF, ix) 1 M LiOH, THF, H₂O, x) BnBr, Et₃N, DMF, xi) Lawesson's reagent, DME, xii) 2 M HCl, THF, xiii) Ph₃P, DEAD, THF, xiv) MnO₂, toluene.


Asymmetric reduction of 2-acetylpyridine (**33**) with Baker's Yeast gave (*S*)-2-(1-hydroxyethyl)pyridine **34**, which was converted to (*1'R*)-2-[1-(*N*-Boc)aminoethyl]pyridine **36** via (*1'R*)-(1-azidoethyl)pyridine **35**. The specific rotation value of **34** thus obtained was $[\alpha]_D^{26} -55.5^\circ$ (*c* 1.6, EtOH) {lit.⁸ $[\alpha]_D -55.5^\circ$ (*c* 1.5, EtOH)}, showing high optical purity (96% ee). Similarly, (*S*)-**36** was also obtained from (*S*)-**34** via successive (*R*)-**34** and (*S*)-**35**, as shown in Scheme 3.

The CD spectra of optically active **29** and (*R*)-**36** showed strong negative Cotton effects at 373 and 270 nm, respectively, while those of **30** and (*S*)-**36** showed positive Cotton effects in the same region. Therefore, it could be determined that the absolute structure of **29** was (*R,S*)-configuration and identical with that of the natural **1**.

Finally, hydrolysis of the *t*-butyl ester of (*1'R*)-**29** with TFA, accompanying deprotection of the Boc group, followed by protection once more with Boc₂O gave the corresponding free acid derivative (*1'R*)-**37**, which was then coupled with the independently prepared precursor of (*P*)-**3**³ by the BOP method to give first the protected Fragment A-B derivative (*P*)-**2**.⁹



Scheme 3. Reagents: i) Baker's Yeast, D-Glucose, H₂O, ii) a) MsCl, Et₃N, CHCl₃, b) NaN₃, DMF, iii) a) H₂, 10% Pd-C, EtOH, b) Boc₂O, Et₃N, CHCl₃, iv) a) MsCl, Et₃N, CHCl₃, b) NaOAc, 15-Crown-5-ether, DMF, c) K₂CO₃, MeOH, H₂O.



Scheme 4. Reagents: i) a) TFA-CHCl₃ (3:2 v/v), b) Boc₂O, Et₃N, CHCl₃, ii) (*P*)-**3**, BOP, (*i*-Pr)₂NEt, DMF.

In conclusion, a convenient synthetic method for the main central 2,3,6-trisubstituted pyridine skeleton of **1** has been sufficiently developed.

This work was supported in part by a Grant-in-Aid for Scientific Research Nos. 10640532 and 12640529 from the Ministry of Education, Science, Sports, and Culture, Japan.

References and Notes

- M. Aoki, T. Othuka, M. Yamada, Y. Ohba, H. Yoshizaki, H. Yasuno, T. Sano, and H. Seto, *J. Antibiot.*, **44**, 582 (1992).
- C. Shin, Y. Nakamura, and K. Okumura, *Chem. Lett.*, **1993**, 1405.
- C. Shin, A. Ito, K. Okumura, and Y. Nakamura, *Chem. Lett.*, **1995**, 45.
- J. P. Sanches, T. F. Mich, and G. G. Huang, *J. Heterocycl. Chem.*, **31**, 297 (1994).
- dppp = 1,3-bis(diphenylphosphino)propane.
- Y. Hamada, M. Shibata, T. Sugiura, S. Kato, and T. Shioiri, *J. Org. Chem.*, **52**, 1252 (1987).
- 29**: Colorless syrup. $[\alpha]_D^{26} -50.9^\circ$ (*c* 0.7, CHCl₃). IR 3435, 3113, 2977, 2931, 2360, 1719, 1606, 1583 cm⁻¹. ^1H NMR (CDCl₃) δ = 1.43 (s, 9H, Boc), 1.46 (d, 3H, CH₂CH, *J* = 6.3 Hz), 1.53 (s, 9H, Bu^t), 3.63 (d, 2H, CH₂SCH, *J* = 9.2 Hz), 5.22 (t, 1H, CHN=C, *J* = 9.2 Hz), 5.39 (s, 2H, PhCH₂), 5.62–5.89 (m, 2H, CHNH), 7.34–7.49 (m, 5H, Ph), 8.17 (s, 1H, pyridine ring-H, *J* = 8.3 Hz), 8.20 (s, 1H, thiazole ring-H), 8.34 (d, 1H, pyridine ring-H, *J* = 8.3 Hz).
- M. Takeshita, K. Terada, N. Akutsu, S. Yoshida, and T. Sato, *Heterocycles*, **26**, 3051 (1987).
- (P)-2**: Colorless syrup. $[\alpha]_D^{22} +11.1^\circ$ (*c* 0.3, CHCl₃). IR 3389, 2929, 2333, 1715, 1684, 1582, 1489, 1438 cm⁻¹. ^1H NMR (CDCl₃) δ = 0.93 and 0.95 (each s, 9H, TPS's Bu^t), 1.29–1.65 (m, 12H, Boc, CH₂CH), 3.62–3.85 (m, 4H, thiazoline's CH₂ × 2), 3.86 (s, 3H, OMe), 3.94–4.14 (m, 2H, CH₂O), 4.32–4.40 (m, 1H, CHCH₂O), 5.28–5.39 (m, 2H, thiazoline's CH × 2), 5.40 (s, 2H, Bn's CH₂), 5.46–5.54 (m, 1H, CONH), 5.63–5.85 (m, 2H, BocNH, CH₂CH), 7.20–7.60 (m, 15H, TPS's Ph × 2, Bn's Ph), 7.98–8.10 (m, 3H, thiazole ring-H × 3), 8.15–8.34 (each d, 2H, pyridine ring-H, *J* = 7.5 Hz).